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Ewing sarcoma is a malignant pediatric bone and soft tissue tumor. Although the 5-year
survival rate of localized disease approaches 75%, the prognosis of metastatic and/or
therapy-resistant disease remains dismal despite the wide use of aggressive therapeutic
strategies. We previously reported that high expression of glutathione S-transferase M4
(GSTM4) in primary tumors correlates with poor patient outcomes. GSTM4 is required for
oncogenic transformation and mediates resistance to chemotherapeutic drugs in Ewing
sarcoma cells. Here, we performed RNA-sequencing analyses of Ewing sarcoma cells and
combined our results with publicly available datasets to demonstrate that GSTM4 is a major
GST specifically expressed in Ewing sarcoma. Pharmacological inhibition of GSTM4 activ-
ity using a pan GST inhibitor, 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX),
significantly limited cellular proliferation and oncogenic transformation of Ewing sarcoma
cells. Moreover, combined use of NBDHEX and etoposide synergistically increased cyto-
toxicity, suggesting a role for GSTM4 as an inhibitor of apoptosis. Mechanistic studies
revealed that GSTM4 limits apoptosis owing to its ability to interact with Apoptosis Signal-
regulating Kinase 1 (ASK1) and inhibit signaling via the c-Jun N-terminal Kinase axis. To
exploit our observation that GSTM4 expression is specifically up-regulated in Ewing sar-
coma, we tested the effect of a GSTM4-activated anti-cancer agent, O2-(2,4-dinitrophenyl)
1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate or JS-K, on tumor growth and
survival. We found that JS-K robustly decreased Ewing sarcoma cell viability and xenograft
tumor growth and improved overall survival of xenograft mice. Our data suggest that
GSTM4 is a novel therapeutic target for the treatment of high GSTM4-expressing Ewing
sarcoma. Strategies that combine standard chemotherapy with agents that inhibit GSTM4,
that are activated by GSTM4, or that block GSTM4/ASK1 interactions, can potentially be
more specific and/or efficacious than standard therapeutic approaches.
Keywords: GSTM4, Ewing sarcoma, NBDHEX, JS-K, drug resistance
INTRODUCTION
Glutathione S-transferases (GSTs) comprise a family of detoxifi-
cation enzymes that catalyze the conjugation of glutathione with
carcinogens, drugs, toxins, and products of oxidative stress (1,
2). It is believed that the function of these enzymes is to reduce
the incidence of deleterious interactions between reactive toxic
species and cellular components. GSTs are highly polymorphic
and can be divided into eight subfamilies, α (GSTAs), κ (GSTKs),
µ (GSTMs), ω (GSTOs), pi (GSTPs), θ (GSTTs), ζ (GSTZs), and
membrane-bound GSTs (MGSTs). Each subfamily is composed
of several members with similarities in either primary sequence
or structure (3). Although GSTs may utilize “common” substrates
such as CDNB (1-chloro-2,4-dinitrobenzene) in vitro, individual
GSTs have unique substrate specificities, suggesting that each fam-
ily member plays a defined role in biotransformation of drugs or
reactive compounds.
Glutathione S-transferases have been implicated in the devel-
opment of resistance to cancer chemotherapeutic agents (4). High
levels of GST expression have been reported in a number of
tumors compared to normal tissues. Overexpression of MGST1
and GSTP1 was found to induce doxorubicin and cisplatin resis-
tance in MCF-7 breast cancer cells (5), pointing at their potential
functional roles in chemoresistance. Consistently, high MGST1
expression in Ewing sarcoma correlates with poor prognosis due
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to doxorubicin resistance (6). It seems that GSTs play two distinct
roles in the development of drug resistance. First, the enzymes
can directly inactivate anti-cancer agents that act as substrates by
catalyzing their conjugation to GSH. Second, GSTs can inhibit the
MAP kinase pathway and limit apoptosis induced by drugs that
are not GST substrates (7–9). Because of their overexpression in a
wide variety of cancers and their key role in drug resistance, GST
inhibition has emerged as a promising therapeutic approach to
limit resistance to cancer therapeutics.
Ewing sarcoma is the second most common pediatric bone
and soft tissue tumor. Current treatment for this malignancy
consists of local control via surgery and/or radiation, and inten-
sive chemotherapy. For patients with localized disease, expected
survival rates are reaching 75% with these aggressive therapies.
However, the outcome for patients with metastatic tumors remains
poor, with a 5-year survival <30%. Novel treatment strategies tar-
geting specific regulators of Ewing sarcoma are urgently needed.
Most cases of Ewing sarcoma are driven by the fusion oncoprotein
EWS/FLI that results from a chromosomal translocation between
chromosomes 11 and 22. EWS/FLI is an aberrant transcription
factor that deregulates expression of target genes, leading to the
tumorigenic and undifferentiated phenotypes of Ewing sarcoma
(10). We previously reported that GSTM4,a relatively new member
of theµ class of GSTs, is a direct, up-regulated, target of EWS/FLI.
Patients who express high GSTM4 levels in their primary tumors
have worse outcomes compared with those whose tumors express
lower levels of GSTM4 (11). In addition, GSTM4 actively con-
tributes to tumorigenesis and drug resistance in Ewing sarcoma.
Knockdown of GSTM4 decreases oncogenic transformation and
increases the sensitivity of Ewing sarcoma cells to chemotherapeu-
tic drugs. These combined observations suggest that GSTM4 is a
promising novel target to treat Ewing sarcoma.
MATERIALS AND METHODS
CELL LINES AND REAGENTS
Ewing sarcoma cell lines A673 and TC71 were purchased from
American Type Culture Collection (ATCC, Manassas, Virginia)
and were cultured as previously described (12). Growth curve and
soft agar colony formation assays were performed as before (12).
Etoposide was purchased from Sigma (St. Louis, MO, USA). NBD-
HEX was synthesized as previously described (13). Briefly, NBD
chloride (1 mmol) and 6-mercapto-1-hexanol (2 mmol) were dis-
solved in 20 mL of a 1:1 (v/v) mixture of ethanol and 0.1 M
potassium phosphate buffer (pH 7.0) at room temperature. The
resulting mixture was stirred for 6 h. The product, NBDHEX, was
collected by filtration and washed twice with distilled water and
dried in vacuo. JS-K was synthesized as previously described (14).
CONSTRUCTS
The construct pcDNA3–ASK1 was generously provided by Dr.
Sheng-Cai Lin (Xiamen University, China). GSTM4 full length
construct and deletion mutants GSTM4-NT and GSTM4-CT were
generated by amplifying the full length, 1–222 and 223–656 bp of
GSTM4, respectively, by PCR and cloning the fragments into the
pCS2-MT vector. RNAi constructs for GSTM4 (GSTM4-4-RNAi
and GSTM4-5-RNAi) and control (Luc-RNAi) were generated and
used as previously described (11).
MTT CELL PROLIFERATION ASSAY
A673 or TC71 cells were seeded in a 24-well plate at a density of
5× 104 cells/well and then incubated at 37°C for 24 h. Following
drug addition, the cells were cultured for 72 h. Each condition
was performed in triplicate. MTT assays were carried out using
a reagent provided by Cayman Chemical (10009365, Ann Arbor,
MI, USA), and following recommendations provided by the man-
ufacturer. Bliss combination index (CI) values were calculated
to assess synergistic (CI <1), additive (CI= 1), or antagonistic
(CI >1) effects of combined drugs on cytotoxicity as previously
described (15).
RNA-SEQ AND DATA ANALYSIS
Total RNA was extracted from Ewing sarcoma cells and treated
with DNase using a Qiagen (Germantown, MD, USA) RNeasy
kit. Messenger RNA was enriched by oligo-dT magnetic beads
and was used to construct Illumina sequencing libraries. The
libraries were single end-sequenced on Illumina Genome Analyzer
IIx for 36 cycles. Reads were mapped to the hg19 genome build
with Casava. The RNA-seq analysis was carried out using USeq
(useq.sourceforge.net) version 8.1.5. Sorted mapped files were
converted to PointData representation with the USeq Eland Parser
application. The raw data can be accessed from the Sequence Read
Archive (SRA) database (accession number SAMN01163407).
IMMUNOPRECIPITATION AND IMMUNOBLOTTING
Immunoprecipitation and immunoblotting were carried out as
previously described (16). Anti-ASK1 (sc-5294 and sc-390275)
and anti-Myc (sc-40) antibodies were from Santa Cruz Biotechnol-
ogy (Dallas, TX, USA). Anti-Jun N-terminal kinase (JNK) (9252)
was from Cell Signaling Technology (Beverly, MA, USA).
KINASE ASSAY
Jun N-terminal kinase kinase assays were carried out using a
non-radioactive MAPK/JNK kinase assay kit from Cell Signal-
ing Technology (Beverly, MA, USA), following the manufacturer’s
instructions.
ANIMAL ENGRAFTMENT AND TREATMENT
To test the efficacy of combined etoposide and NBDHEX treat-
ment, TC71 cells (1× 106) were injected with matrigel into the
flanks of 4–6-week-old female nude mice. Mice were randomly
grouped into four groups 24 h after injection. Mice in the control
group were treated with vehicle [0.5% Methocel (w/v)] only; ani-
mals in the “etoposide” group received a single dose of etoposide
(18 mg/kg, i.p.); the “NBDHEX” group consisted of mice receiv-
ing 40 mg/kg of NBDHEX daily for 7 days by gavage; and the
“combination”group included treatments with both etoposide and
NBDHEX. To test the efficacy of JS-K, TC71 cells (1× 106) were
injected with matrigel into both flanks of 4–6-week-old nude mice,
followed by vehicle (2.25% Pluronic® P123 in PBS/2% DMSO) or
JS-K treatment (6µmol/kg) intravenously starting 24 h later and
continuing every other day for 2 weeks. Tumor growth was moni-
tored by caliper measurement; three-dimensional tumor volumes
were calculated using the equation (Length×Width×Depth)/2.
The p-value for tumor growth curve was determined by the
ANOVA test using GraphPad Prism. The mice were sacrificed once
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a tumor reached a size of 2 cm. Percent survival was plotted as
Kaplan–Meier survival curves using GraphPad Prism. The p-value
was determined by the log-rank (Mantel–Cox Test) method using
GraphPad Prism. Animal experiments were performed following
approval from the University of Utah Institutional Animal Care
and Use Committee.
RESULTS
GSTM4 IS ONE OF THE MAJOR GSTs EXPRESSED IN EWING SARCOMA
We previously found that GSTM4 is an up-regulated target of the
Ewing sarcoma oncoprotein EWS/FLI (11). To determine whether
this feature is unique to GSTM4 or common to other GST mem-
bers, we characterized the expression profile of all known GST
family members in patient-derived A673 Ewing sarcoma cells using
RNA-seq (17). We found that GSTM4 is expressed at high levels
and ranks fourth among 17 members of the family (Figure 1A).
In addition to GSTM4, GSTP1, GSTO1, and MGST3 are prevalent
GSTs in A673 cells. We next asked whether GSTM4 is also highly
expressed in Ewing sarcoma from human patients. Using a pub-
licly available gene expression profile dataset of 19 Ewing sarcoma
tumors (18), we again found that GSTM4 was one of the major
GSTs expressed in Ewing sarcoma tumors (Figure 1B). We pre-
viously reported that EWS/FLI regulates GSTM4 expression via a
GGAA microsatellite in the promoter region of the GSTM4 gene
(11). Notably, this GGAA microsatellite regulatory element is not
present in any other GST promoters, suggesting that GSTM4 may
be specifically expressed in Ewing sarcoma due to expression of the
EWS/FLI oncoprotein in these malignancies. To investigate this
issue, we compared GSTM4 expression levels in various sarcoma
tumors using the Baird et al. data set (18), and in cell lines using
qRT-PCR. We found very low GSTM4 expression in most non-
Ewing sarcoma tumors and cell lines (Figures 1C,D). This analysis
also revealed that high GSTM4 expression was typical of approx-
imately half of the Ewing sarcoma tumors included in the Baird
et al. dataset. This suggests that factors additional to EWS/FLI likely
participate in the regulation of GSTM4 expression. We attempted
to compare GSTM4 protein level in various sarcoma cell lines
and tumors. However, we could not find a GSTM4-specific anti-
body that is capable of detecting GSTM4 at endogenous level.
In conclusion, GSTM4 transcripts constitute one of the major
GST transcripts specifically expressed in Ewing sarcoma cells and
tumors.
INHIBITION OF GSTM4 BY NBDHEX DECREASES CELL VIABILITY AND
INHIBITS ONCOGENIC TRANSFORMATION OF EWING SARCOMA CELLS
Our previous observation that GSTM4 is required for oncogenic
transformation and mediates etoposide resistance of Ewing sar-
coma cells, led us to hypothesize that GSTM4 inhibitory agents
might be cytotoxic and increase the sensitivity of Ewing sarcoma
cells to etoposide. To test this, we treated A673 and TC71 cells with
6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX), an
effective GST inhibitor and new anti-cancer agent. HEK293 and
RH30 cells were used as negative and positive controls, respec-
tively (19). We found drastic decrease in cell proliferation in
RH30, A673, and TC71, but not HEK293 cells in response to
NBDHEX treatment (Figure 2A). This is consistent with a pre-
vious report showing that Ewing sarcoma cell lines are sensitive
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FIGURE 1 | GSTM4 is a major GST specifically expressed in Ewing
sarcoma. (A) Expression levels of all detectable GSTs in A673 cells. Total
RNA extracted from A673 cells was subjected to cDNA library construction
and labeling, followed by next generation sequencing using Illumina
HiSeq1000, as described previously (17). GST genes are ranked by value of
(Continued)
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FIGURE 1 | Continued
FPKM (Fragments per kilobase per million mapped reads). (B) Relative
expression levels of GSTs in tumors from Ewing sarcoma patients.
Expression values of GSTs from the Baird et al. dataset (18) were
normalized to that of MGST1, which was set as 0. (C) GSTM4 expression
levels in tumors from patients with various sarcomas. Data were extracted
from the Baird et al. dataset. Horizontal lines indicate mean values. ANOVA
statistical analysis results are shown (*P <0.05; **P <0.01; ***P <0.001).
(D) GSTM4 expression levels in various sarcoma cell lines. Total RNA was
extracted from Ewing sarcoma (A673, TC71, TC32, EWS502, SKNMC),
rhabdomyosarcoma (RD, RH28, RH30), osteosarcoma (SAOS, U2OS), and
HEK293 cells followed by quantitative RT-PCR analyses. The relative GSTM4
transcript levels normalized to GAPDH were shown. The experiment was
repeated three times and results of one representative repeat are shown as
means±SD of technical triplicate.
to NBDHEX (6). Moreover, when we seeded NBDHEX-treated
cells in soft agar, these cells formed significantly fewer colonies
in the anchorage-independent environment, even when treated
with NBDHEX at concentrations much lower than its reported
IC50 [1µM (19), Figure 2B]. These results indicate that inhi-
bition of GSTM4 decreases cellular proliferation and abolishes
oncogenic transformation. The data are in agreement with our
previous finding that GSTM4 knockdown inhibits oncogenic
transformation (11).
NBDHEX AND ETOPOSIDE HAVE SYNERGISTIC EFFECTS ON
CYTOTOXICITY IN EWING SARCOMA CELLS
We previously found that knockdown of GSTM4 renders Ewing
sarcoma cells more sensitive to etoposide (11). To evaluate whether
GSTM4 inhibition has similar effects, we treated A673 and TC71
cells with NBDHEX, etoposide, or NBDHEX combined with
etoposide. Bliss CI values then were calculated (15) to assess
whether NBDHEX and etoposide have synergistic, additive, or
antagonistic effects on cytotoxicity (CI <1 indicates synergism).
We found that etoposide is more effective when combined with
NBDHEX than either etoposide or NBDHEX alone, indicating a
synergistic effect (Figure 2C). Interestingly, synergism between the
agents was much stronger at low drug levels (Figure 2C). We next
tested if combined NBDHEX and etoposide treatment affected
xenograft tumor growth in vivo. We found robust synergism dur-
ing early phases of tumor development (8 days, Figure 2D). This
effect was less pronounced at later times, as tumors develop-
ing in the combination group continued to grow and reached
sizes only slightly smaller than tumors developing in the single
treatment groups (Figure 2D, ANOVA test p= 0.123). Lack of
significant synergism at later time points may be due to incom-
plete inhibition of GSTM4 by NBDHEX despite daily dosing
for 7 days. NBDHEX forms a covalent sigma complex with glu-
tathione that binds tightly to GSTM4 (13). Thus, while bind-
ing of the inhibitor to the enzyme–substrate complex is tight,
it is reversible, and the slow-tight binding inhibition may lead
a plateau of extended incomplete inhibition with continuous
dosing. We observed no significant difference in overall sur-
vival among the treatment groups. Additionally, the most sig-
nificant and largest inhibition of tumor growth was observed
when both drugs were injected at very low doses, that is, at
levels where single agents had minimal or no effects on tumor
growth (data not shown). These results are consistent with our
findings in cellular models and they suggest that combining NBD-
HEX and etoposide at low drug levels synergistically increases
cytotoxicity, thus minimizing potential high dose-related side
effects.
GSTM4 INTERACTS WITH ASK1 AND INHIBITS ETOPOSIDE-INDUCED
JNK ACTIVATION AND APOPTOSIS
We next investigated the mechanism of GSTM4-mediated resis-
tance to etoposide. We previously found that depletion of GSTM4
caused no significant alterations in reactive oxygen species pro-
duction (11), indicating that the ability of GSTM4 to increase
drug resistance is independent of its transferase activity. In addi-
tion to detoxifying electrophiles and toxic agents by catalyzing
their conjugation to reduced GSH, GSTs can bind to various pro-
teins and serve as regulators of MAP kinase-mediated apoptosis.
Mouse GSTM1 was found to physically interact with Apopto-
sis Signaling Kinase 1 (ASK1), leading to repression of ASK1-
mediated stress-activated signals and apoptosis (9). Similarly,
GSTA1 and GSTP1 have been shown to interact with JNK and
inhibit apoptosis (7, 8).
To investigate whether GSTM4 regulates JNK activation and
apoptosis, we treated control or GSTM4-silenced A673 and TC71
cells with etoposide and then determined the extent of c-Jun
phosphorylation as a measure of JNK activation. We found that
etoposide treatment led to higher JNK activation in GSTM4
knockdown (GSTM4-4 and GSTM4-5 RNAi) cells compared with
control (Luc-RNAi) cells (Figure 3A), indicating that GSTM4
inhibits JNK activation induced by etoposide. We next character-
ized expression of the pro-apoptotic genes BAD, BAX, and CASP3
in etoposide-treated GSTM4- or control-silenced cells. We found
that etoposide had modest or no effect on the expression of these
pro-apoptotic genes in control-knockdown cells (Figure 3B).
In contrast, expression of the three tested genes was robustly
increased in GSTM4-knockdown cells (Figure 3B). These com-
bined data strongly suggest that GSTM4 plays a central inhibitory
role in etoposide-induced JNK activation and apoptosis.
To investigate the mechanism by which GSTM4 inhibits apop-
tosis, we assessed whether GSTM4 interacts with pro-apoptotic
kinases in a manner similar to that of other GSTs. We focused our
attention on a panel of kinases in the MAPK pathway including
JNK, p38, MKK4, MKK7, ASK1, and MEKK1. Immunoprecipita-
tion analyses showed that ASK1, but not other kinases tested (not
shown), robustly binds to GSTM4 (Figure 3C). To identify the key
GSTM4 region responsible for interaction with ASK1, we gener-
ated GSTM4 deletion mutants, GSTM4-NT and GSTM4-CT, in
which the substrate binding site and GSH binding site of GSTM4
are absent, respectively (Figure 3D, upper panel). Immunopre-
cipitation studies using these deletion mutants showed that the
C-terminal end of GSTM4 is required for interaction with ASK1
(Figure 3D, lower panel). However, further studies are necessary
to determine whether this interaction is direct.
To study the mechanism whereby GSTM4/ASK1 complexes
inhibit etoposide-induced JNK activation and apoptosis, we over-
expressed ASK1 and GSTM4 at various ratios, evaluated the
extent of GSTM4/ASK1 complex formation, and then assessed the
extent of phosphorylation of MKK4, the MAP2K that functions
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FIGURE 2 |The GST inhibitor NBDHEX inhibits Ewing sarcoma cell
proliferation and oncogenic transformation and increases the efficacy
of etoposide. (A), NBDHEX inhibits Ewing sarcoma cell growth in culture.
Ewing sarcoma TC71 and A673 cells, rhabdomyosarcoma RH30 cells, and
HEK293 cells were subjected to treatment with the indicated
concentrations of NBDHEX. Cell proliferation was assessed by MTT assays.
The experiment was repeated three times and results of one representative
repeat are shown as means±SD of technical triplicate. (B) NBDHEX inhibits
colony formation of Ewing sarcoma cells in soft agar. TC71 and A673 cells
were treated with NBDHEX at the indicated concentrations, and then were
seeded in soft agar to assess anchorage-independent growth. The
experiment was repeated three times and results of one representative
repeat are shown as means±SD of technical duplicate. Asterisk indicates
p<0.05. (C) NBDHEX and etoposide act synergistically in inducing
cytotoxicity of Ewing sarcoma cells. Cells were treated with NBDHEX,
etoposide, or NBDHEX together with etoposide, as indicated. Cellular
proliferation was then assessed by MTT assays, and bliss combination index
(CI) was calculated and represented as a heatmap. CI <1 indicates
synergism, =1 additive effect, and >1 antagonism. (D) Effect of combined
NBDHEX and etoposide treatment on Ewing sarcoma xenograft tumors.
TC71 cells were injected subcutaneously into both flanks of nude mice.
NBDHEX, etoposide, or NBDHEX plus etoposide were administered 24 h
after cell injection. Tumor growth was monitored by caliper measurement
twice a week. Each group contained 5 animals with total of 10 tumors. The
experiment was repeated three times and results of one representative
repeat are shown as average of 10 tumors±SD. ANOVA test indicates the
differences in tumor growth between combination group and the other
three groups are not statistically significant (p=0.123).
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increases JNK activation induced by etoposide. Control- (Luc-RNAi) and
GSTM4-silenced (GSTM4-4-RNAi and GSTM4-5 RNAi) cells were treated
with or without etoposide (20µg/ml) for 3 h. Cell lysates were subjected to
JNK immunoprecipitation and JNK kinase assays using c-jun as the
substrate. The result shown is representative of three experimental
repeats. (B) Decreasing GSTM4 levels increases apoptosis induced by
etoposide. Control-silenced (Luc-RNAi) and GSTM4-silenced
(GSTM4-4-RNAi and GSTM4-5 RNAi) cells were treated with or without
etoposide, as in (A) above. Expression levels of GSTM4, BAD, BAX, and
CASP3 then were evaluated by qRT-PCR analyses. “ns” indicates not
significant, *p<0.05, **p<0.01. Fold-change in expression levels before
and after etoposide treatment are indicated. The result shown is
representative of three experimental repeats. (C), GSTM4 interacts with
ASK1. Cells were transfected with ASK1, myc-GSTM4, or ASK1 together
with myc-GSTM4. Cell lysates were subjected to immunoprecipitation
using an anti-ASK1 antibody and the amount of co-immunoprecipitated
GSTM4 was assessed using an anti-myc antibody. The result shown is
representative of three experimental repeats. (D), ASK1 binds to the
C-terminal domain of GSTM4. Cells were transfected with ASK1 and/or
GSTM4 deletion mutants, and processed as indicated in (C) above. HC,
heavy IgG chain; LC, light IgG chain. The result shown is representative of
three experimental repeats. (E), Binding of GSTM4 to ASK1 inhibits MKK4
phosphorylation. Cells were transfected with ASK1 and increasing
amounts of GSTM4, as indicated. MKK4 phosphorylation was analyzed by
immunoblot analysis, using an anti-phosphorylated MKK4 (Thr261)
antibody.The result shown is representative of three experimental repeats.
downstream of ASK1, and that is required for JNK phospho-
rylation and activation. We found that as interaction between
GSTM4 and ASK1 increased, the extent of MKK4 phosphory-
lation decreased (Figure 3E). Taken together, our data suggest that
GSTM4 binds to ASK1 and inhibits JNK activation and apoptosis
induced by etoposide, thus increasing resistance of Ewing sarcoma
cells to this commonly used cancer therapeutic agent.
THE GST-ACTIVATED PRO-DRUG JS-K INHIBITS CELLULAR
PROLIFERATION AND XENOGRAFT TUMOR GROWTH VIA GSTM4
Since GSTM4 is a major GST specifically expressed in EWS/FLI-
driven Ewing sarcoma cells and tumors, drugs preferen-
tially activated by GSTM4 (i.e., GSTM4 pro-drugs) may be
attractive therapeutics to target drug-resistant Ewing sarcoma.
O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]
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diazen-1-ium-1,2-diolate or JS-K is a GST-activated pro-drug
and a member of the O2-aryl diazeniumdiolate compound fam-
ily. Activation of JS-K by GSTs releases nitric oxide (NO) and
induces apoptosis (20). JS-K has shown promise as a novel can-
cer therapeutic agent in a number of studies (20–22), but its
utility for the treatment of pediatric cancers has not been pre-
viously evaluated. Our initial studies showed that JS-K inhibits
the proliferation of A673 and TC71 Ewing sarcoma cells in a
dose-dependent fashion (Figure 4A). To assess whether GSTM4
is required for this response, we knocked down GSTM4 in A673
and TC71 cells and then treated control- or GSTM4-silenced cells
with increasing concentrations of JS-K. We found that limiting
JS-K metabolism by silencing GSTM4 decreased sensitivity to the
drug (Figure 4B). These results indicate that GSTM4 is required
for JS-K-mediated inhibition of cellular proliferation in Ewing
sarcoma cells. We next assessed whether JS-K decreases tumor
growth in xenograft models. TC71 cells were injected into the
flanks of nude mice and, 24 h after injection, JS-K was adminis-
tered every other day for a 2-week period. We found that treatment
with JS-K significantly reduced tumor growth (Figure 4C,ANOVA
Test p= 0.023) and increased overall survival (Figure 4D, Mantel–
Cox Test, p= 0.0002), strongly suggesting that this GSTM4 pro-
drug has anti-tumorigenic effects that can be exploited for the
treatment of Ewing sarcoma.
DISCUSSION
Glutathione S-transferases comprise a family of enzymes involved
in cellular detoxification. Increasing evidence suggests that GSTs
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FIGURE 4 | JS-K is a GSTM4-activated drug that abolishes cell
proliferation and xenograft tumor growth. (A) JS-K is effective in inhibiting
TC71 and A673 Ewing sarcoma cell growth. TC71 (left) and A673 (right) cells
were seeded in 24-well plates, allowed to grow to confluence, and then
treated with the indicated concentrations of JS-K for 72 h. MTT assays then
were performed to assess cellular proliferation. The experiment was repeated
three times and results of one representative repeat are shown as
means±SD of technical duplicate. (B) GSTM4-silenced cells are more
resistant to JS-K. Control-silenced (Luc-RNAi) or GSTM4-silenced
(GSTM4-4-RNAi and GSTM4-5 RNAi) TC71 (left) or A673 (right) cells were
subjected to JS-K treatment, as indicated. Cellular proliferation was assessed
by MTT assays. The experiment was repeated three times and results of one
representative repeat are shown as means±SD of technical duplicate.
Asterisk indicates that the difference between control-silenced and
GSTM4-silenced cells is significant (p<0.05); ns, not significant. (C) JS-K
inhibits Ewing sarcoma xenograft tumor growth in immunodeficient mice.
TC71 cells were injected subcutaneously into both flanks of nude mice. JS-K
was administered via tail vein injection the day after cell injection every other
day for 2 weeks. Tumor growth was monitored by caliper measurement twice
a week. The experiment was repeated four times and results of one
representative repeat are shown as means±SD of 10 tumors in each group.
ANOVA test, p=0.023. (D) Overall survival of vehicle or JS-K-treated mice
harboring tumor xenografts. Kaplan–Meier survival curve was plotted using
GraphPad Prism. Mantel–Cox Test, p=0.0002.
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play an important role in cancer biology. GST expression is
increased in tumors compared with normal tissues (23), resulting
in resistance to cancer chemotherapeutic agents (24). Expression
of a number of GSTs appears to be inversely associated with
patient survival (6), suggesting that GSTs are promising targets
for therapeutic intervention.
We, and others, have observed that GSTM4 is a consistently
up-regulated GST in Ewing sarcoma cell lines and Ewing, but
not other, sarcomas from human patients. GSTM4 is transcrip-
tionally controlled by the fusion oncoprotein EWS/FLI through a
specific regulatory element unique to the GSTM4 promoter. This
observation places GSTM4 as a key GST specifically expressed
in Ewing sarcoma, a finding with potentially useful therapeutic
implications for the treatment of this type of tumor. High GSTM4
expression in primary tumors positively correlates with poor out-
comes and increased resistance to etoposide and fenretinide in
Ewing sarcoma. In addition, GSTM4 expression is required for
oncogenic transformation. Here, we evaluated the potential utility
of pharmacologically targeting GSTM4 in Ewing sarcoma. Since
GSTM4-specific substrates and inhibitors have not been identi-
fied to date, we initially utilized NBDHEX, a broad GST-targeting
agent that binds the µ class of GSTs such as GSTM4 with high
affinity (25). NBDHEX has been shown to be cytostatic for Ewing
sarcoma cells (19) and has synergistic and additive effects when
combined with doxorubicin and vincristine, respectively (6, 19).
In our studies, NBDHEX decreased cell viability and inhibited
oncogenic transformation, and acted synergistically with etopo-
side in Ewing sarcoma cells. Considering that etoposide resistance
correlates with GSTM4 expression in Ewing sarcoma (11), the
observed synergistic effects of NBDHEX and etoposide likely are
due to inhibition of GSTM4.
We complemented our NBDHEX inhibition studies with a
second strategy that took advantage of high GSTM4 expression
in Ewing sarcoma. Pro-drugs are inactive precursors that, when
metabolized by target cells, generate biologically active agents that
affect intracellular events. We tested a GST-activated pro-drug, JS-
K, for its effect on the growth of Ewing sarcoma cells in vitro and
in vivo. JS-K was designed as a novel cancer therapeutic agent that
releases nitric oxide (NO) when activated by GSTs; this pro-drug
has shown promise for the treatment of multiple malignancies,
including breast cancer and leukemias (20, 26). Molecular analy-
ses in cellular models showed that JS-K inhibits the growth of
Ewing sarcoma cells in a GSTM4-dependent fashion, and that this
feature is recapitulated in in vivo settings. This is the first study
reporting the potential utility of JS-K as a novel pharmacologic
agent for the treatment of a pediatric tumor.
Our study also contributes novel mechanistic insight related to
the drug resistance induced by GSTM4 in Ewing sarcoma. First,
we observed that GSTM4 inhibits etoposide-induced apoptosis by
targeting the JNK signaling axis. Second, we demonstrated that
the C-terminus of GSTM4 directly or indirectly interacts with
the apoptosis-inducing kinase ASK1, limiting phosphorylation of
MKK4 by ASK1. This suggests that agents that disrupt the for-
mation of GSTM4/ASK1 complexes or that reactivate the MAPK
apoptotic pathway could potentially overcome drug resistance in
Ewing sarcoma. The relationship between signaling through the
MAPK pathway and drug sensitivity is further supported by a
previous report showing that sensitivity to the apoptotic agent
fenretinide is dependent on activation of p38 and JNK MAPKs in
Ewing sarcoma cells (27).
Taken together, our studies point at GSTM4 as a key player and
novel therapeutic target in Ewing sarcoma. Targeting of GSTM4
can be achieved via at least three approaches (Figure 5). Firstly,
GSTM4 inhibitors such as NBDHEX can be used to limit onco-
genic transformation and increase the efficacy of pro-apoptotic
chemotherapeutic agents. Secondly, GSTM4-activated pro-drugs
such as JS-K can selectively target high GSTM4-expressing malig-
nant cells and spare normal cells and tissues, thus limiting unde-
sirable side effects. Thirdly, specific disruption of GSTM4/ASK1
interactions can potentially reactivate apoptosis, thus decreasing
chemoresistance to existing therapeutic agents. Future studies in
preclinical and clinical settings are required to fully evaluate the
efficacy of targeting GSTM4 as a novel strategy to manage Ewing
sarcoma.
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